PSEN1 and Alzheimer disease: Since iBECs carrying AD-associated PSEN1 mutation previously demonstrated prolonged recovery post FUS in vitro [84], GC could be trialed to reduce inflammation and support barrier closure in familial AD patients who could be at risk of extended BBB disruption.